AngioDynamics, Inc. (NASDAQ:ANGO)

CAPS Rating: 5 out of 5

The Company is a provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease and local oncology therapy options for treating cancer.

Results 1 - 17 of 17

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/3/2014 11:54:36 AM : Outperform Start Price: $15.53 ANGO Score: -15.59

ANGO BP 15 TP 18 1YR REV 50%

Recs

0
Member Avatar WilliamCrook2003 (70.97) Submitted: 11/15/2013 3:43:56 AM : Outperform Start Price: $15.56 ANGO Score: -20.91

MF Stock of the day.

Recs

0
Member Avatar TerryHoodSr (54.12) Submitted: 7/29/2013 10:57:07 PM : Outperform Start Price: $14.55 ANGO Score: -12.93

growth

Recs

0
Member Avatar IfHeDiesHeDies (75.12) Submitted: 4/8/2013 7:22:14 PM : Outperform Start Price: $10.58 ANGO Score: +4.73

A+

Recs

5
Member Avatar KatWoman50 (< 20) Submitted: 3/7/2008 9:11:31 PM : Outperform Start Price: $10.05 ANGO Score: -20.71

Provider of medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive diagnosis and treatment of cancer and peripheral vascular disease.
Acquired RITA in 2007 and now has a diverse product line that includes radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.
Advance guidence on 3Q sales growth of 14% missed wallstreets expectations and sent the stock down 37% for the day. BUY BUY BUY

Recs

1
Member Avatar oceana1225 (< 20) Submitted: 7/17/2007 8:08:03 AM : Outperform Start Price: $17.86 ANGO Score: -56.61

I would see this as a trade based mainly on the charts. It seems to have support at just under $16.00. It's come down considerably and seems to be trending up currently trading at 17.99. It's already told the street that it has problems, so, presumably, those are "priced into"the stock. I think it may still "shock" the street with an earnings shortfall, and, I think I'll wait until earnings to do anything with it, but after that, I think it could trend back up to about 20 or 21 per share which would be a significant gain in a short time. On the other hand, it has problems -- patent litigation and still "in the red." Longer term, I see it as volatile and certainly in a great market for the baby boomers but on the pricey side given its performance. And, it seems to have low debt, it would be a good company to possibly be taken out.

Recs

0
Member Avatar junkopadna (< 20) Submitted: 4/21/2007 1:58:23 PM : Outperform Start Price: $17.33 ANGO Score: -60.77

I'm picking this one simply because I see a few of the CAPS leaders who have picked it as "outperform," yet it has since done poorly. So this is just an experiment. I'm just blindly guessing that it's oversold.

Recs

0
Member Avatar e2nelson (72.22) Submitted: 4/19/2007 4:40:51 PM : Underperform Start Price: $16.16 ANGO Score: +55.13

Angiodynamics recently purchased Rita Medical and in the assimilation of that purchase along with losing a patent dispute to DioMed Holdings will depress revenues in the short term.

Recs

1
Member Avatar diefendb (66.87) Submitted: 3/13/2007 9:56:25 PM : Underperform Start Price: $22.86 ANGO Score: +89.55

I expect them to take a hit in litigation vs. Diomed.

Recs

0
Member Avatar grochen (33.87) Submitted: 2/27/2007 11:57:40 PM : Outperform Start Price: $23.55 ANGO Score: -90.47

Copied downwithpumpers (same day later)

Recs

0
Member Avatar ValueIsValuable (75.48) Submitted: 2/27/2007 1:48:29 PM : Outperform Start Price: $23.54 ANGO Score: -88.36

Um, lots of great analysis here. No brainer.

Recs

5
Member Avatar razormd (78.04) Submitted: 2/19/2007 8:44:33 PM : Outperform Start Price: $25.00 ANGO Score: -88.58

Rita acquisition completed -- will enhance market position and broaden customer base...however, Oncobionic acquisiton is the main story here...my review of the research they've done so far suggests that their electrophoration technology will replace radiofrequency and cryosurgical techniques of tumor ablation...it can treat tumor cells situated next to blood vessels that the other techniques have difficulty with...also important is that it works on the cell membranes and so leaves the underlying connective tissue intact -- this makes for very rapid (weeks versus months) revovery time...this technology could make the company the proverbial "10 bagger" that everyone wishes for...some patent lawsuits involving Diomed and Venus muddy the water short-term but they don't appear to be significant impediments longer term.

Recs

0
Member Avatar Milesatrets (< 20) Submitted: 1/21/2007 12:47:44 PM : Outperform Start Price: $23.62 ANGO Score: -87.85

With the acquisition of RITA Medical this stock is poised to grow though 2008.

Recs

0
Member Avatar TradeMarket (93.75) Submitted: 1/4/2007 7:28:17 PM : Outperform Start Price: $21.46 ANGO Score: -82.74

Well managed, great growth and like the matchup with RITA...bullish!

Recs

0
Member Avatar synergyltd (< 20) Submitted: 10/18/2006 7:11:01 PM : Outperform Start Price: $23.21 ANGO Score: -94.04

this is clearly a $28-30 dollar stock that had a minor hiccup and is on the way back up

Recs

1
Member Avatar felberdud (< 20) Submitted: 9/29/2006 3:52:21 PM : Outperform Start Price: $21.21 ANGO Score: -91.48

Medical Device Industry player with many new products coming. Get in now!!!

Recs

0
Member Avatar miroshns (40.38) Submitted: 8/19/2006 9:53:05 AM : Outperform Start Price: $18.26 ANGO Score: -85.99

Oversold on options charge

Results 1 - 17 of 17

Featured Broker Partners


Advertisement